词条 | Poseltinib |
释义 |
| drug_name = | INN = | type = | IUPAC_name = N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide | image = Poseltinib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1353552-97-2 | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 56644522 | DrugBank = | synonyms = HM-7122; LY 3337641 | C=26|H=26|N=6|O=3 | smiles = C=CC(NC1=CC=CC(OC2=C(OC=C3)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O }}Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.[1] Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.[2] References1. ^{{cite web|author=Alternative Names: HM 71224; LY 3337641 |url=https://adisinsight.springer.com/drugs/800037569 |title=Poseltinib - AdisInsight |publisher=Adisinsight.springer.com |date= |accessdate=2017-05-22}} {{pharma-stub}}2. ^{{cite web|url=https://investor.lilly.com/releasedetail.cfm?ReleaseID=902448 |title=Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (NYSE:LLY) |publisher=Investor.lilly.com |date=2015-03-19 |accessdate=2017-05-22}} 4 : Experimental drugs|Acrylamides|Piperazines|Pyrimidines |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。